SPPI Has A Better Game Than Puma. Sadly, The Game Has Been Taken Over By The Short Funds With Good HFT Programs. If The Word Gets Out And Some Of The Puma Rich Jump In to SPPI In The Next Couple Of Days You Could Make Your Bad Trade Good. Spectrum Has Been Controlled By Shorts But, Beleodaq And A Pfizer Buyout Offer Will Change All Of That In A Huge Way.
cbmngmt: Seeing 5 thumbs down on my positive post really inspires me to recommend that you take the largest short position you can margin your way into. PUMA winners will try for a repeat with SPPI, a much better company to play. Pawn your cars and buy some more shares to sell short.
Sell All Today. Then take half of your profit and double it by going long SPPI. Huge short squeeze will develop in next couple of days as the 10th most shorted biotech gets the attention and money from the Puma Biotechnology winners. Check out their actual profitable drug lines and their newest drug, Beleodaq that launched today. Spectrum Pharmaceuticals.website will show you why they are not a one trick pony.
SPPI #10 Most Shorted Biotech With 60 Million Float. Beleodaq, Their 5th Oncology Drug Is Launching Today.
With over 25% of shares sold short, SPPI was the number 10 most shorted biotech as last reported. After 2 years of torture by short fund HFT traders, it's time they got the attention of new investors who may have made a bunch of money today on Puma. It's marketed product lines fund drug development and acquisition with it's positive cash flow from what was the 4 oncology / hematology drugs they market. Today they launched their 5th oncology drug Beleodaq. The FDA gave it accelerated approval. Spectrum Pharmaceuticals also has 3 late stage development drugs in addition to the 9 very promising drugs being developed, some of which would be entering into a 6 billion dollar annual sales market.
How does SPPI cash flow drop like a rock with their 5th new drug launching today. Are you working the short side on that stock also. If so I am hopping you get the PBYI treatment.
Then Take Your Money And Go Buy Some Stock In A Real Drug Company, With Real Cash Flow, 5 Marketed Drugs In Oncology and Hematology. The newest drug Beleodaq, launching today. SPPI Spectrum Pharmaceuticals. Go to their website and see what a real drug company with real drugs looks like. The Shorts have about 30 % of the stock sold short. Trading $7.06 now 60 million shares. If you hate shorts you will love the short squeeze on this stock.
Lot's of disinformation will be posted to obscure truth about products and pipeline. New investors that love short squeezes are on the way.
With over 30% of shares sold short, SPPI was the number 10 most shorted biotech as last reported. It's product lines fund drug development and acquisition with it's positive cash flow from what was the 4 oncology/hematology drugs they market. Today they launched their 5th oncology drug Beleodaq. The FDA gave it accelerated approval. SPPI also has 3 late stage development drugs in addition to the 9 very promising drugs being developed, some of which would be entering into a 6 billion dollar annual sales market. After 2 years of torture by short fund HFT traders, it's time they got the attention of new investors along with a hug and a good SQUEEZE.
Spectrum needs the attention of the investors that have never looked at it before and have come to the PBYI board because of the short squeeze that has taken place today. Make your case for SPPI on that board and lets get some new investors that are not short funds with great HFT alogo's. Today is the day for showing off the company and it's newest drug launch to a new pool of investors. A good short squeeze will be great for the company and the long suffering long investors.
5 marketed drugs in oncology and hematology and a pipeline that is paid for with cash flow from operations. A Great 3 drug very near term pipeline and 9 very promising drugs in advanced development. ALL that and more with a stock price of $7.08 on 60 million outstanding shares, thanks to short manipulation. ANOTHER SHORT SQUEEZE IN THE MAKING.
The Eyeballs are on the PBYI board today and we really need to get them to take a look at SPPI who was #10 on the most shorted stock list; Joe and Caveman should get a couple of posts up on the PBYI board and help bring some attention to the HUGE short Squeeze potential for Spectrum, a company that is so much more that PBYI.
Check out their 4 marketed hematology/oncology drugs and a near term pipeline of 3 late-stage drug candidates include Belinostat, an HDAC inhibitor in late-stage clinical development for peripheral T-cell lymphoma, and other solid tumors (including Carcinoma of Unknown Primary origin, etc.), Apaziquone, a synthetic bio-reductive agent being investigated in the treatment of non muscle-invasive bladder cancer, and Captisol-enabled® Melphalan, a new IV formulation of melphalan that has the potential to offer multiple advantages for clinicians and patients in the multiple myeloma transplant setting. Both drugs are being developed under Special Protocol Assessment (SPA) by the FDA.
This stock was the number 10 most shorted even though it funds final development of licensed and acquired drugs with positive cash flow from what was 4 drugs marketed until today when they launched their 5th. The latest drug is Beleodaq which was given accelerated approval. They also have another 9 very promising drugs in development.
Treatments that involve self medication at home seem to be the preferred form on any drug. Once available in US patient counts will rise because of preference over infusions.
It is related to today's launch
If they give brown paper bags of jasmine scented $100 bills to the SEC investigators they move on to the next complaint where they give away scented $100 bills in bags. It is all about efficiency.
That might be of interest to some of the retail longs that are left.
Thanks for the thumbs down string. Better outcomes for a fatal disease is really a negative thing in your short sighted, paid basher world.